fda compounding glp-1 enforcement news 🚨 Moves to Permanently Shut Down Compounded GLP-1s The FDA is taking steps to eliminate large-scale of medications like semaglutide and tirzepatide, signaling a major shift in how these FDA is short-sighted on compounding

Worth watching if you prefer hearing a physician walk through the rationale rather than reading it

T2DM must be considered as consequent to obesity and is also associated with acute and chronic stress and systemic proinflammatory state

doi: 10.1159/000521264 Summary Keywords GLP-1R agonists, obesity, weight-reducing drugs, metabolic diseases, dual agonism Citation Wang J-Y, Wang Q-W, Yang X-Y, Yang W, Li D-R, Jin J-Y, Zhang H-C and Zhang X-F (2023) GLP1 receptor agonists for the treatment of obesity: Role as a promising approach

Geisinger Health Building a Resilient CDI: Implementing a Second-Level Review Marie Mathieu, MS, RN, NE-BC, CDIP, CCDS